Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial

Taylor, Walter; Thriemer, Kamala; von Seidlein, Lorenz; Yuentrakul, Prayoon; Assawariyathipat, Thanawat; Assefa, Ashenafi; Auburn, Sarah; Chand, Krisin; Hoàng Châu, Nguyễn; Yeong Cheah, Phaik; Thanh Dong, Le; Dhorda, Mehul; Degaga, Tamiru; Devine, Angela; L. Ekawati, Lenny; Fahmi, Fahmi; Hailu, Asrat; Anwar Hasanzai, Mohammad; Tinh Hien, Tran; Khu, Htee; Ley, Benedikt; Lubell, Yoel; Marfurt, Jutta; Mohammad, Hussein; A. Moore, Kerryn; Nader Naddim, Mohammad; Pitaloka Pasaribu, Ayodhia; Pasaribu, Syahril; Promnarate, Cholrawee; Ghulam Rahim, Awab; Sirithiranont, Pasathron; Solomon, Hiwot; Sudoyo, Herawati; Sutanto, Inge; Viet Thanh, Ngo; Thi Tuyet-Trinh, Nguyen; Waithira, Naomi; Woyessa, Adugna; Yamin, Fazal; M. Dondorp, Arjen; A. Simpson, J.; Kevin Baird, J.; J. White, Nicholas; Day, Nicholas; N. Price, Ric

doi:10.1016/s0140-6736(19)31285-1

Public

Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial

Published in The Lancet • Jul 18, 2019

Authors:

Walter Taylor

Kamala Thriemer

Lorenz von Seidlein

Abstract

BACKGROUND: Primaquine is the only widely used drug that prevents Plasmodium vivax malaria relapses, but adherence to the standard 14-day regimen is poor. We aimed to assess the efficacy of a shorter course (7 days) of primaquine for radical cure of vivax malaria. METHODS: We did a randomised, doubl...

Subject

Primaquine

Medicine

Malaria

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!